Börse:
53,895€
-0,49%
Echtzeit-Aktienkurs Cambrex Corp
Bid:
53,340€
Ask:
54,450€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 1,81 Mrd. EUR (33,61 Mio. x 53,895€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 3,95 | 3,56 | 3,31 | 3,41 |
| KGV | 30,62 | 21,73 | 17,61 | 19,63 |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Cambrex Corp Aktie
Börsenkurse Cambrex Corp
| Lang & Schwarz | 53,370€ | 462 | 54,370€ | 462 | 53,870€ | -0,41% |
| Dollar Indikation | 59,083$ | 0 | 60,194$ | 0 | 59,638$ | 0,18% |
| Börse Stuttgart | 53,340€ | 2000 | 54,450€ | 2000 | 53,895€ | 0,48% |
| Euro Indikation | 53,340€ | 0 | 54,450€ | 0 | 53,895€ | -0,49% |
Fundamentaldaten der Cambrex Corp Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 531,19 Mio. | 109,81 Mio. | 92,42 Mio. | 2,75 | 0,00% | 19,63 | 3,41 |
| 2017 | 535,01 Mio. | 141,83 Mio. | 102,45 Mio. | 3,06 | 0,00% | 17,61 | 3,31 |
| 2016 | 490,34 Mio. | 127,54 Mio. | 81,68 Mio. | 2,48 | 0,00% | 21,73 | 3,56 |
| 2015 | 433,93 Mio. | 89,57 Mio. | 57,22 Mio. | 1,76 | 0,00% | 30,62 | 3,95 |
| 2014 | 374,43 Mio. | 45,51 Mio. | 57,30 Mio. | 1,81 | 0,00% | 29,78 | 4,48 |
| 2013 | 318,31 Mio. | 45,01 Mio. | 25,92 Mio. | 0,84 | 0,00% | 64,16 | 5,16 |
| 2012 | 276,78 Mio. | 31,37 Mio. | 62,30 Mio. | 2,06 | 0,00% | 26,16 | 5,82 |
| 2011 | 255,51 Mio. | 19,94 Mio. | 10,97 Mio. | 0,37 | 0,00% | 145,66 | 6,24 |
| 2010 | 224,94 Mio. | 14,97 Mio. | 9,65 Mio. | 0,33 | 0,00% | 163,32 | 7,05 |
| 2009 | 235,23 Mio. | 22,65 Mio. | 10,39 Mio. | 0,36 | 0,00% | 149,71 | 6,71 |
Profil der Cambrex Corp Aktie
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen